The FTC is setting its sights on generative AI

The FTC is setting its sights on generative AI

Watershed technological transitions can usher in opportunities for new entrants to challenge market leaders. These rare paradigm shifts redefine how companies compete for customers and resources. The emergence of generative artificial intelligence (AI) is a quintessential example of how innovation can either disrupt or entrench dominant incumbents depending on how markets and regulators respond.

These approaches might include physical therapy, yoga, Tramadol Next Day Delivery or acupuncture, all of which Real Klonopin online have shown promise in alleviating muscle tightness and discomfort without the risk of side effects like paresthesia. Unfortunately, these reactions might reinforce a negative feedback loop where the anxiety Ambien Online exacerbates asthma symptoms, creating an ongoing struggle Ativan Overnight Shipping for the patient. This reflects a growing recognition in the field of medicine that treating chronic conditions like osteoarthritis requires not only addressing the physical symptoms but also taking into account the emotional and psychological states of the patients. Healthcare providers Trusted site to Buy Ambien have been working closely with patients to not only understand their pain but also to discuss the potential benefits and risks associated with various treatments. The integration of mental health care into Soma For Sale Online primary health settings is another trend that has gained traction. This trend is particularly Order Pregabalin Online relevant when considering the cognitive symptoms Soma Without A Prescription associated with various conditions. Effective pain Real Xanax online management, whether Lorazepam Purchase Online through on-label or off-label medication use, should be approached in a thoughtful and patient-centered manner. It highlights the importance of integrating mental health support into pain management programs. Open communication Buy Soma 350 Mg Online can lead to shared decision-making, where patients and providers collaboratively decide on a path that respects the patient’s overall health goals and lifestyle.

Generative AI uses massive models trained on rich and diverse datasets to create new content. This revolutionary tool is reshaping how businesses interact with their customers, competitors, and partners, creating immense opportunity and great risk.

The Federal Trade Commission (FTC) is making a case for aggressive antitrust enforcement. A recent Technology Blog submission from the Bureau of Competition and Office of Technology staff outlines several practices that could trigger government intervention. To understand antitrust risk when competing in markets affecting generative AI, businesses should familiarize themselves with the parameters and limits of several common antitrust theories of harm.

Companies often seek to shore up suppliers or customers through exclusive deals. Exclusive dealing is not necessarily problematic and often stimulates competition. But agreements that enable one firm to control a critical input, distribution channel, or customer segment can raise concerns. In McWane v. FTC, for example, a federal court condemned an exclusive-dealing arrangement that foreclosed rivals from “distribution sufficient to achieve efficient scale, thereby raising costs and slowing or preventing effective entry.”

Generative AI startups should familiarize themselves with the parameters and limits of several common antitrust theories of harm.

In the context of generative AI, the FTC foresees antitrust exposure where “incumbents that offer both compute services and generative AI products” wield such arrangements to discriminate against new entrants. The FTC appears poised to scrutinize exclusive deals involving compute resources, such as graphical processing units, that are key to competing for generative AI markets.

Although each agreement requires an individualized assessment, several general principles are worth knowing. First, exclusive-dealing arrangements should not be implemented as part of a scheme to exclude or deny rivals the ability to compete. Exclusive-dealing contracts that block competitors from scaling are inherently risky.

Second, companies should contemporaneously document any pro-competitive benefits, such as lower costs, higher quality, and better access to products, and should be prepared to explain specifically how the exclusivity results in improved products or services. Finally, be aware that exclusive arrangements with companies whose market share exceeds 30% are riskier.

Source @TechCrunch

Leave a Reply